Advances in Nanomedicine for Cancer Theranostics

Cancer is one of the foremost reasons for global death. According to estimates, around 19.3 million instances of cancer and over 10 million fatalities were documented in the year 2020, making it one of the leading causes of death across the globe. There are still restrictions due to the absence of effective early detection and inadequate conventional therapy, which has led to poor prognosis and survival rates. This is the case despite the fact that there have been breakthroughs in diagnosis and treatment. The science of nanomedicine has achieved considerable advancements in the realm of cancer theranostics. These advancements offer a number of distinct advantages, including tumor-targeting through the increased permeability and retention effect, biocompatibility, and small size. In light of the above, the purpose of the Focus Issue on 'Advances in Nanomedicine for Cancer Theranostics', was introduced to highlight new research on nanomedicine-based approaches to cancer treatment. These techniques include drug and gene delivery, bioimaging, biomarker identification, diagnosis, immunotherapy, biosensors, and other precision oncology strategies. For this Focus Issue, we invited front-line researchers and authors who contributed the original research papers and topical review articles. This editorial summarizes the published articles of this collection which includes eighteen research articles and eleven review articles.